Allergy shot study for grass and cypress pollen symptoms
Part of Ear, nose & throat, Immune system & allergy, Lungs & breathing clinical trials.
This phase 3 trial tests a specific allergy treatment (an “immunotherapy” shot) for people whose symptoms are triggered by grass and cypress tree pollen. It aims to see if the treatment is safer and more effective at reducing allergy symptoms over time, especially for nose/eye symptoms and some people with asthma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to join the study in writing after a consent discussion.
- You’re between 12 and 65 years old, inclusive.
- Your allergy symptoms (hay-fever type) fit moderate-to-severe rhinitis/rhinoconjunctivitis, and are linked to grass and/or cypress pollen.
- Your allergy tests must show strong sensitivity: a positive skin prick test to grass and to cypress, and blood allergy antibodies (specific IgE) above a set level.
- If you can become pregnant, you must have a negative pregnancy test and use reliable birth control during the study.
- You must be able to follow the schedule and have a smartphone for tracking symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether an allergy treatment can reduce symptoms caused by grass and olive pollen. It also checks safety, especially for breathing and allergic reactions, in people with confirmed grass/olive allergy.
This Phase 3 study tests whether dust-mite allergy treatment (likely allergy shots) can reduce allergy symptoms and improve safety. It focuses on people whose nose/eye allergy is triggered by house dust mites and who may also have controlled asthma.
This trial tests an under-the-tongue tablet for people with dust mite allergies causing moderate to severe nasal symptoms or mild-to-moderate asthma. The goal is to see if it improves symptoms and can replace or reduce the need for allergy medicines.
This study checks how well a newer, detailed allergy test (using specific allergen components) can guide whether you should get allergy immunotherapy (allergy shots) for things like dust mites or grass pollen. It may help patients get the right treatment plan by improving how doctors confirm what allergens are driving symptoms.
This study tests a new allergy shot (PollenVax) given under the skin to treat seasonal allergies caused by mugwort pollen. If you have moderate-to-severe mugwort allergies confirmed by testing, this trial may help reduce your symptoms during pollen season.
This trial tests a new allergy shot (ITI-9001) for people with Japanese cedar pollen allergy. It aims to see if the shot is safe and can reduce allergy symptoms. The study is for people who have not tried immunotherapy before.
Hear when a new Rhinoconjunctivitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.